Table 3. Association Between Bcr-Abl TKI Use and Incident Hepatitis B Flare, Stratified by Sex and Age.
| TKI use prior to index date, d | Rate ratio (95% CI)a | |||
|---|---|---|---|---|
| Male patients | Female patients | Patients by age, y | ||
| <50 | ≥50 | |||
| 60 | 1.14 (0.72-1.81) | 3.20 (1.70-6.03) | 1.38 (0.63-3.02) | 1.36 (0.91-2.04) |
| 90 | 1.31 (0.84-2.05) | 3.44 (1.86-6.39) | 1.82 (0.86-3.85) | 1.44 (0.97-2.14) |
| 120 | 1.32 (0.85-2.06) | 3.74 (2.04-6.86) | 1.72 (0.82-3.60) | 1.56 (1.06-2.30) |
| 180 | 1.30 (0.84-2.02) | 3.63 (2.00-6.57) | 1.87 (0.91-3.86) | 1.49 (1.02-2.18) |
| 365 | 1.29 (0.84-1.98) | 3.61 (2.03-6.40) | 1.81 (0.88-3.73) | 1.57 (1.09-2.26) |
Abbreviation: TKI, tyrosine kinase inhibitors.
a
Rate ratios were estimated by the conditional logistic regression. Covariates considered in the models were Bcr-Abl TKI use, cancer history in 6 months prior to the index date, cirrhosis, transplantation for the hematologic malignancies, and other medications that are well known for their hepatitis B flare or HBV reactivation risk (ie, immunosuppressants, cytotoxic chemotherapy, and rituximab). In the primary analysis, case patients were those who received their first antiviral agent for more than 28 days with no evidence of receiving chemotherapy within 30 days after index date.